Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade A 177.95 -0.74% -1.32
SGEN closed down 1.47 percent on Wednesday, September 23, 2020, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SGEN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup -0.74%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.74%
NR7 Range Contraction -0.74%
Multiple of Ten Bearish Other -0.74%
Inside Day Range Contraction -0.74%
Wide Bands Range Expansion -0.74%
Overbought Stochastic Strength -0.74%
1,2,3 Pullback Bullish Bullish Swing Setup -2.20%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.20%
Calm After Storm Range Contraction -2.20%
Older End-of-Day Gignals for SGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 2 hours ago
Down 2 % about 3 hours ago
Down 1% about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Medicine Biotechnology Cancer Treatment Of Cancer Monoclonal Antibodies Chemotherapy Lymphoma Antibody Drug Conjugates Seattle Genetics Therapies For Cancer Non Hodgkin Lymphoma Renal Cell Carcinoma Adc Metastatic Pancreatic Cancer Castration Resistant Prostate Cancer Cd30 Chemotherapy Regimen Hodgkin Lymphoma

Is SGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 187.985
52 Week Low 75.49
Average Volume 977,325
200-Day Moving Average 139.29
50-Day Moving Average 164.31
20-Day Moving Average 161.97
10-Day Moving Average 171.51
Average True Range 5.65
ADX 33.33
+DI 34.06
-DI 13.45
Chandelier Exit (Long, 3 ATRs ) 165.42
Chandelier Exit (Short, 3 ATRs ) 160.55
Upper Bollinger Band 188.29
Lower Bollinger Band 135.66
Percent B (%b) 0.83
BandWidth 32.49
MACD Line 5.62
MACD Signal Line 2.46
MACD Histogram 3.158
Fundamentals Value
Market Cap 25.63 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -125.36
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 183.62
Resistance 3 (R3) 183.80 182.52 182.90
Resistance 2 (R2) 182.52 181.42 182.44 182.65
Resistance 1 (R1) 180.90 180.73 180.26 180.72 182.41
Pivot Point 179.62 179.62 179.31 179.54 179.62
Support 1 (S1) 178.00 178.52 177.36 177.82 176.13
Support 2 (S2) 176.72 177.83 176.64 175.89
Support 3 (S3) 175.10 176.72 175.65
Support 4 (S4) 174.92